Tenaya Therapeutics (TNYA)
(Real Time Quote from BATS)
$2.02 USD
+0.27 (15.43%)
Updated Oct 17, 2024 02:10 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Tenaya Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 105 | 187 | 251 | 129 | 27 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 7 | 4 | 1 | 1 |
Total Current Assets | 112 | 194 | 255 | 130 | 28 |
Net Property & Equipment | 43 | 51 | 43 | 17 | 10 |
Investments & Advances | 0 | 18 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 6 | 5 | 4 | 1 | 1 |
Total Assets | 171 | 279 | 314 | 148 | 38 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 10 | 11 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 11 | 9 | 3 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 1 | 2 |
Total Current Liabilities | 23 | 24 | 22 | 5 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 4 | 5 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 31 | 36 | 36 | 9 | 9 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 221 | 73 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 543 | 523 | 434 | 2 | 1 |
Retained Earnings | -403 | -279 | -156 | -83 | -44 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 139 | 243 | 279 | 139 | -44 |
Total Liabilities & Shareholder's Equity | 171 | 279 | 314 | 148 | 38 |
Total Common Equity | 139 | 243 | 279 | -81 | -117 |
Shares Outstanding | 68.10 | 66.80 | 41.20 | NA | NA |
Book Value Per Share | 2.05 | 3.64 | 6.76 | 0.00 | 0.00 |
Fiscal Year End for Tenaya Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 99 | 122 | 105 | 122 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 6 | 6 | 7 | 5 |
Total Current Assets | NA | 105 | 129 | 112 | 127 |
Net Property & Equipment | NA | 39 | 41 | 43 | 45 |
Investments & Advances | NA | 0 | 0 | 0 | 6 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 5 | 6 | 6 | 6 |
Total Assets | NA | 163 | 185 | 171 | 193 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 7 | 6 | 6 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 9 | 8 | 13 | 10 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 17 | 19 | 23 | 19 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 29 | 27 | 31 | 29 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 599 | 594 | 543 | 538 |
Retained Earnings | NA | -465 | -436 | -403 | -373 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 134 | 158 | 139 | 165 |
Total Liabilities & Shareholder's Equity | NA | 163 | 185 | 171 | 193 |
Total Common Equity | 0 | 134 | 158 | 139 | 165 |
Shares Outstanding | 78.80 | 78.50 | 78.50 | 68.10 | 67.80 |
Book Value Per Share | 0.00 | 1.71 | 2.02 | 2.05 | 2.43 |